Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ariad Pharm Inc (ARIA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,663,416
  • Shares Outstanding, K 194,390
  • Annual Sales, $ 118,800 K
  • Annual Income, $ -231,160 K
  • 36-Month Beta 2.16
  • Price/Sales 24.94
  • Price/Cash Flow N/A
  • Price/Book 0.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.17
  • Most Recent Earnings -0.12 on 11/07/16
  • Next Earnings Date 02/28/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.63 +1.52%
on 01/27/17
23.99 unch
on 02/15/17
+0.30 (+1.27%)
since 01/13/17
3-Month
11.69 +105.22%
on 12/22/16
23.99 unch
on 02/15/17
+10.79 (+81.74%)
since 11/15/16
52-Week
4.67 +413.70%
on 02/24/16
23.99 unch
on 02/15/17
+19.27 (+408.26%)
since 02/12/16

Most Recent Stories

More News
Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious...

CRBP : 7.00 (-1.41%)
DNPUF : 13.6000 (+4.62%)
ARIA : 23.99 (+0.17%)
MRK : 54.35 (-0.04%)
MDCO : 30.94 (-1.46%)
LLY : 84.03 (+0.42%)
MTZPY : 20.9750 (-0.07%)
BMY : 61.43 (+0.47%)
MKKGY : 21.2200 (-0.89%)
Corbus Pharmaceuticals Appoints Paris Panayiotopoulos to Its Board of Directors

NORWOOD, MA--(Marketwired - October 17, 2017) - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious...

CRBP : 7.00 (-1.41%)
DNPUF : 13.6000 (+4.62%)
ARIA : 23.99 (+0.17%)
MRK : 54.35 (-0.04%)
MDCO : 30.94 (-1.46%)
LLY : 84.03 (+0.42%)
MTZPY : 20.9750 (-0.07%)
BMY : 61.43 (+0.47%)
MKKGY : 21.2200 (-0.89%)
ALUNBRIG(TM) (brigatinib) Approved for the Treatment of ALK+ Metastatic Non-Small Cell Lung Cancer, Available for Order at Biologics, Inc.

Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, has been selected by Takeda Pharmaceutical Company Limited, through its wholly-owned subsidiary...

ARIA : 23.99 (+0.17%)
TKPYY : 27.8800 (+1.01%)
Akcea Therapeutics Announces Appointment of Edward Fitzgerald to Board of Directors

Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced the appointment of Edward Fitzgerald to the company's board of directors. Mr. Fitzgerald, former...

ARIA : 23.99 (+0.17%)
IONS : 54.53 (+0.35%)
The Medicines Company Appoints Paris Panayiotopoulos to Its Board of Directors

The Medicines Company (NASDAQ:MDCO) today announced that it has appointed Paris Panayiotopoulos to its Board of Directors. Mr. Panayiotopoulos, who will serve as a Class I director, will...

MKGAY : 38.3600 (-0.62%)
ARIA : 23.99 (+0.17%)
MRK : 54.35 (-0.04%)
MDCO : 30.94 (-1.46%)
LLY : 84.03 (+0.42%)
Takeda Completes Acquisition of ARIAD Pharmaceuticals, Inc.

--- Accretive to FY2018 Underlying Core Earnings -

ARIA : 23.99 (+0.17%)
Biotech Stock Roundup: Amgen, Gilead Report 4Q Results, ARIAD Seeks EU Nod for Brigatinib

Although both Amgen (AMGN) and Gilead reported better-than-expected 4Q results, the companies provided a disappointing sales outlook for 2017.

STML : 14.45 (-1.70%)
ARIA : 23.99 (+0.17%)
GWPH : 128.15 (+1.40%)
GILD : 72.46 (-0.49%)
REGN : 384.85 (-0.69%)
AMGN : 170.12 (+0.09%)
BIIB : 308.97 (-0.27%)
Blog Coverage Exelixis Partners with Takeda to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan

Upcoming AWS Coverage on ARIAD Pharmaceuticals

ARIA : 23.99 (+0.17%)
TKPYY : 27.8800 (+1.01%)
EXEL : 25.85 (-1.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology. The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and...

See More

Key Turning Points

2nd Resistance Point 24.02
1st Resistance Point 24.01
Last Price 23.99
1st Support Level 23.96
2nd Support Level 23.92

See More

52-Week High 23.99
Last Price 23.99
Fibonacci 61.8% 16.61
Fibonacci 50% 14.33
Fibonacci 38.2% 12.05
52-Week Low 4.67

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart